FDA Approves Merck's First-of-Its-Kind Cholesterol Pill Lipfendra

What happened

The FDA approved Lipfendra, a once-daily pill from Merck designed to lower cholesterol beyond statins alone. This approval adds a new cardiovascular product to Merck's launch pipeline, which is critical as the company navigates the Keytruda loss-of-exclusivity and Gardasil China headwinds. However, Lipfendra's near-term revenue contribution is expected to be modest relative to Merck's $66B+ revenue base, and the company still faces a ~$2.5B 2026 headwind from generics and IRA pricing. The approval supports the bull case in the DeepValue report, which assumes new launches can accelerate, but does not change the base case of a flat 2026. The market will need to see commercial execution before assigning material value to Lipfendra.

Implication

Lipfendra adds to Merck's post-Keytruda growth arsenal, but with Keytruda representing 49% of sales and the 2028-2029 LOE cliff approaching, a single cholesterol pill is insufficient to bridge the gap. The approval marginally improves the bull case ($145), but the base case ($125) and bear case ($95) remain intact. The key re-rating catalysts remain Gardasil China restart and containment of the $2.5B headwind.

Thesis delta

The prior thesis centered on Merck's 2026 holding pattern and need for proof of diversification. This FDA approval provides incremental evidence of launch pipeline progress, but the core thesis remains unchanged: MRK is still a show-me story until Gardasil China resumes and the $2.5B headwind is absorbed. The approval does not materially shift the risk/reward.